Heterogeneity of KRAS, NRAS, PIK3CA and BRAF mutational status in primary tumour, lymph nodes and liver metastases in sporadic colorectal cancer

2018 ◽  
Author(s):  
Sofia Del Carmen
Keyword(s):  
Colorectal Cancer ◽  
Lymph Nodes ◽  
Liver Metastases ◽  
Primary Tumour ◽  
Sporadic Colorectal Cancer ◽  
Mutational Status

scholarly journals The role of genetic instability in stimulation of angiogenesis in liver metastases of sporadic colorectal cancer

HPB ◽  
2019 ◽  
Vol 21 ◽  
pp. S660
Author(s):  
W. Otto ◽  
F. Macrae ◽  
J. Sierdzinski ◽  
M. Król ◽  
M. Feliksbrot-Bratosiewicz ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Liver Metastases ◽  
Genetic Instability ◽  
Sporadic Colorectal Cancer ◽  
Stimulation Of

The utility of PET scanning in colorectal cancer liver metastases being considered for surgery.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e14519-e14519
Author(s):  
Jeffri R. M. Ismail ◽  
Ciara Marie Kelly ◽  
Marian Hanrick ◽  
Cara Regan Downey ◽  
Lauragh McCarthy ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Liver Resection ◽  
Local Recurrence ◽  
Lymph Nodes ◽  
Liver Metastases ◽  
Preoperative Staging ◽  
Definitive Treatment ◽  
Preoperative Imaging ◽  
Colorectal Cancer Liver Metastases ◽  
Pet Scanning

e14519 Background: Liver resection remains the only potentially curative option for a subset of patients with colorectal cancer liver metastases (CRCLM). Preoperative imaging used to determine resectability includes computed tomography (CT), magnetic resonance imaging (MRI) and positron emission tomography (PET). The objective of this study was to determine the utility of PET scanning for potentially resectable CRCLM. Methods: We retrospectively reviewed a prospectively maintained database for all patients considered for resection of CRCLM from July 2010 to July 2012 in two specialist colorectal/hepatobiliary cancer centres. We extracted and analyzed data with respect to preoperative staging imaging and definitive treatment performed on completion of staging. Results: We identified 100 patients who underwent preoperative staging investigations for potentially resectable CRCLM. The imaging techniques performed included: CT (n=99, 99%), MRI liver (n=75, 75%), PET (n= 96, 96%). In 22 (22/96, 23%) patients PET scanning added to the preoperative staging information, identifying local recurrence (n=3, 3.1%), confirming liver metastases following an inconclusive CT/MRI (n=2, 2.1%), outruling liver metastases (n=1, 1%) and identifying extrahepatic sites (EHS) suspicious for disease (n=16, 16.7%). The EHS included either lung (n=6), bone (n=2), peritoneum (n=1) or lymph nodes (n=7). There were 2 false positive results. One patient with FDG-avid mediastinal lymph nodes had no cancer on endobronchial biopsy. One patient with FDG avidity at the primary anastomosis had no evidence of disease at colonoscopy. PET definitively changed the therapeutic strategy in 16 patients (16/96, 16.6%): precluding liver resection in 10 patients (10/96, 10.4%), leading to resection of extrahepatic disease in 4 patients (4/96, 4.1%), resection of local recurrence in 1 patient (1/96, 1%) and resection of hepatic metastases in one patient (1/96, 1%). Conclusions: In this small retrospective cohort the addition of metabolic imaging altered management in 16.6% of patients with potentially resectable CRCLM. There is a need for randomized evidence to support the routine use of PET in addition to cross-sectional imaging in this setting.

scholarly journals Quantitative CT imaging features correlate with colorectal cancer liver metastases (CLM) mutational status

HPB ◽  
2018 ◽  
Vol 20 ◽  
pp. S56-S57
Author(s):  
R.M. Marcus ◽  
D.T. Fuentes ◽  
H.A. Lillemoe ◽  
A. Qayyum ◽  
T.A. Aloia
Keyword(s):  
Colorectal Cancer ◽  
Liver Metastases ◽  
Ct Imaging ◽  
Imaging Features ◽  
Quantitative Ct ◽  
Colorectal Cancer Liver Metastases ◽  
Mutational Status

scholarly journals The role of ccr5 polymorphism in colorectal cancer and liver metastasis in the Tunisian population

2021 ◽  
pp. 44-44
Author(s):  
Marwa Weslati ◽  
Rahma Boughriba ◽  
Donia Ounissi ◽  
Meriam Hazgui ◽  
Sonia Marghali
Keyword(s):  
Colorectal Cancer ◽  
Liver Metastasis ◽  
Liver Metastases ◽  
Protective Factor ◽  
Significant Risk ◽  
Tunisian Population ◽  
Wild Type ◽  
Ccr5 Expression ◽  
Ccr5 Gene ◽  
Mutational Status

Chemokines and their receptors are involved in cancer initiation and progression, including colorectal cancer (CRC) and liver metastasis formation. Our aim was to elucidate C-C chemokine receptor type 5 (CCR5) gene polymorphism (CCR5?32) impact on CRC and colorectal cancer liver metastases (CRLM) occurrence risk. We analyzed the CCR5 gene mutational status in 108 primary CRC cases, 35 CRLM and 248 healthy individuals, and evaluated CCR5 expression in healthy tissue and tumors. Rare allele ??32? was more frequent in controls (7.2% vs 2.8% in CRC). All 35 metastases had wild-type CCR5. Our analysis showed that CCR5 wild type has a significant risk of 2.73-fold (95% CI=1.22-7.31) to cause CRC while ?32 reduced the risks 0.36-fold (95% CI=0.13-0.82). For CRC, CCR5 correlated with left-sided tumors and liver metastases (P=0.040 and P= 0.039 respectively). As for CRLM, no correlation was found. Immunohistochemical profile analysis of CCR5 revealed a significant association with the male gender (P=0.049) and non-mucinous carcinomas (P< 0.001) in primary CRC. CCR5 expression revealed an association with the degree of tumor differentiation for both CRC and CRLM (P < 0.001). CCR5?32 might be a protective factor against CRC development and dissemination.

ATTACHE: A phase III, multicenter, randomized comparison of chemotherapy given prior to and post surgical resection versus chemotherapy given post surgical resection for hepatic metastases from colorectal cancer.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. TPS3643-TPS3643
Author(s):  
Jonathan Fawcett ◽  
Katrin Marie Sjoquist ◽  
Rob Padbury ◽  
Christopher Christophi ◽  
Niall Christopher Tebbutt ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Adjuvant Chemotherapy ◽  
Liver Metastases ◽  
Surgical Resection ◽  
Operative Treatment ◽  
Primary Tumour ◽  
Hepatic Metastases ◽  
Phase Iii ◽  
Treatment Needs

TPS3643 Background: No randomized studies have directly compared the role of peri-operative to adjuvant chemotherapy for resectable liver metastases. Benefit from post operative compared to peri-operative treatment has been suggested in a recent retrospective study of 499 patients with resected colorectal liver metastases which showed improved survival with entirely post-operative chemotherapy. Given this data and that of the small randomised trials demonstrating improved surgical outcomes with adjuvant chemotherapy, the role of entirely post-operative chemotherapy as a means of improving outcomes while reducing the negative effects of pre-operative treatment needs to be examined. Methods: 200 patients randomized 1:1 to 6 months of treatment post-operatively or 3 months of treatment pre-operatively and 3 months post-operatively. Site investigators will nominate chemotherapy schedule (mFOLFOX6, XELOX or FOLFIRI when adjuvant oxaliplatin received previously) prior to randomisation. Primary endpoint: proportion of patients in each arm with surgical complications within 30 days. Secondary endpoints: proportion of patients completing planned chemotherapy, post operative mortality rate (in each group), tolerability and safety of treatment, response rate by RECIST V1.1 and CEA, time to progression, time to treatment failure, overall survival, QoL (EORTC QLQ-C30 and QLQ-LMC21). A planned prospective meta-analysis with MRC (UK) and NSABP C-11 trials will have sufficient power to examine the effect of schedule (peri- or post-operative) on progression free survival (PFS). Eligibility: Patients with histologically proven colorectal cancer with radiologically confirmed, resectable liver metastases without evidence of extra-hepatic disease are eligible. Patients with synchronous metastases who have undergone resection of the primary tumour are eligible but patients requiring combined resection of primary cancer and liver metastatic disease are excluded. Patients with involved hilar nodes or wound implant metastases will not be eligible. Trial Status: Study opened to accrual August 2011.

A randomized clinical trial of chemotherapy compared to chemotherapy in combination with cetuximab in k-RAS wild-type patients with operable metastases from colorectal cancer: The new EPOC study.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. 3504-3504 ◽  
Author(s):  
John Neil Primrose ◽  
Stephen Falk ◽  
Meg Finch-Jones ◽  
Juan W. Valle ◽  
David Sherlock ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Clinical Trial ◽  
Liver Metastases ◽  
Egf Receptor ◽  
Primary Tumour ◽  
Data Monitoring Committee ◽  
Progression Free Survival ◽  
Study Data ◽  
Wild Type ◽  
Free Survival

3504 Background: Resection of liver metastases from colorectal cancer with or without neoadjuvant chemotherapy is the standard of care. The EPOC study (Nordlinger et al, Lancet 2008) randomised patients between surgery and surgery with chemotherapy and demonstrated an improvement in 3 year progression free survival (PFS) of 7·3% (from 28·1% to 35·4%). As a rational extension to the EPOC study data, the New EPOC study evaluates the benefit of cetuximab, an EGF receptor antibody, in addition to standard chemotherapy in patients with operable liver metastases. Methods: 272 patients were randomised between February 2007 and November 2012 into the New EPOC study. Eligible patients were required to be k-RAS wild type, have operable liver metastases and to be sufficiently fit for chemotherapy and surgery. Patients with the primary tumour in situ, and those who required short course rectal radiation were eligible. Patients were randomised to receive a fluoropyrimidine and oxaliplatin plus or minus cetuximab for 12 weeks before, then 12 weeks following surgery. Patients who had been treated with adjuvant oxaliplatin could receive irinotecan and 5 – fluorouracil. Results: Following a recommendation from the Independent Data Monitoring Committee on 19/11/2012, the New EPOC study was stopped when the study met a protocol pre-defined futility analysis. With 45.3% (96/212) of the expected events observed, progression free survival was significantly worse in the cetuximab arm (14.8 vs 24.2 months, HR (95%CI) 1.50037 (1.000707 to 2.249517) p< 0.048). The result of a pre-planned analysis excluding the 23 patients treated with irinotecan based chemotherapy was similar (15.2 vs 24.2 months, HR 1.565546 (1.014967-2.414793) P<0.043). Conclusions: Although the data are immature, the accumulation of more events is unlikely to change this result. In patients with resectable liver metastases and K-RAS wt tumours the addition of cetuximab to chemotherapy is not beneficial. Clinical trial information: ISRCTN22944367.

Sign in / Sign up

Export Citation Format

Share Document